AstraZeneca, revenues up 8% in Q1 to 15.3 billion

AstraZeneca opens 2026 with growing results, buoyed by the performance of its oncology and rare disease drugs, and confirms its medium- to long-term targets. In the first quarter of this year, the Anglo-Swedish biopharmaceutical multinational reported total revenues of $15.3 billion, up 8% at constant exchange rates, driven by double-digit growth in higher value-added segments. On the profitability front, core operating profit rose by 12%, while core earnings per share (EPS) increased by a smaller 5%, impacted by the comparison with a more favourable tax rate in the same period last year and stood at$2.58. The core tax rate stood at 21%, with the group confirming its full-year forecast in the range of 18% to 22%.

"We posted solid growth in Q1 2026, with revenues in excess of $15 billion, demonstrating our continued commercial effectiveness," said CEO Pascal Soriot. "We are going through a catalyst-rich phase, with positive results for four Phase III programmes since the last quarter, including early data for two important new molecules."

In addition to the financial results, the quarter highlights significant progress in research and development. Since the publication of its Q4 2025 accounts at the end of March, AstraZeneca has reported positive outcomes for four high-value Phase III programmes, including the first pivotal data on two new molecular entities (NMEs): tozorakimab, intended for the treatment of chronic obstructive pulmonary disease (COPD), and efzimfotase alfa, developed for hypophosphatasia.

In parallel, the group obtained 14 authorisations in the main geographical areas, further strengthening the product portfolio in view of the next marketing steps.

The group continues to invest in commercial capabilities to support planned launches, while further clinical upgrades are expected later this year. AstraZeneca reiterated that it is 'on track' with its strategic ambitions set to 2030, confirming a pipeline that is considered among the most robust in the global pharmaceutical industry.